Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Second filgrastim biosimilar approved by FDA

U.S. FDA Approves Pfizer’s Biosimilar NIVESTYM™ (filgrastim-aafi), Pfizer press release

Nivestym (filgrastim-aafi), a biosimilar to Neupogen (filgrastim) was approved July 20 by the Food and Drug Administration, according to a statement provided by the agency. Nivestym is the second biosimilar to Neupogen to be approved in the United States.

Nivestym is approved for the same indications as Neupogen and can be prescribed for:

  • Patients with cancer receiving myelosuppressive chemotherapy.
  • Patients with acute myeloid leukemia receiving induction or consolidation chemotherapy.
  • Patients with cancer undergoing bone marrow transplantation.
  • Patients undergoing autologous peripheral blood progenitor cell collection and therapy.
  • Patients with severe chronic neutropenia.

Prescribing information is available here.

Citation:

U.S. FDA Approves Pfizer’s Biosimilar NIVESTYM™ (filgrastim-aafi), Pfizer press release

This Week's Must Reads

Gene sequencing sheds light on outcomes in MPN, Grinfeld J et al. N Engl J Med. 2018;379:1416-30

Phase 2 trial evaluates entospletinib in DLBCL, Burke JM et al. Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):e327-e331

Obesity lowers risk of death in PE patients, Khan Z et al. CHEST. 2018 Oct. doi: 10.1016/j.chest.2018.08.919

T cell infusion effective in PML, Muftuoglu M et al. N Engl J Med. 2018 Oct 11;379:1443-51

Must Reads in AML

T cell infusion effective in PML, Muftuoglu M et al. N Engl J Med. 2018 Oct 11;379:1443-51

Race and pruritus create cancer risk picture, Kwatra SG et al. J Am Acad Dermatol. 2018 Sep 11. doi: 10.1016/j.jaad.2018.08.044.

Levofloxacin prophylaxis in ALL, AML , Alexander S, et al. JAMA. 2018;320(10):995-1004

Higher AML, MDS risk linked to autotransplants, Radivoyevitch T et al. Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160-7

Vadastuximab talirine improves AML remission rates, Fathi AT et al. Blood. 2018 Jul 25. doi: 10.1182/blood-2018-03-841171.